Core Insights - Windtree Therapeutics, Inc. has appointed Leanne Kelly as an independent director and chair of the audit committee, enhancing the board's expertise [1][3] - Ms. Kelly brings over 20 years of experience in finance and management within the life sciences and technology sectors, having held various executive roles [2] - The company aims to become a revenue-generating biotech by acquiring small biotech firms with FDA-approved products, leveraging its equity for these acquisitions [3] Company Overview - Windtree Therapeutics focuses on developing innovative therapies for critical conditions, with a portfolio that includes istaroxime, a Phase II candidate for acute heart failure [3] - The company also has preclinical candidates targeting heart failure and oncology applications, alongside a licensing business model with existing partnerships [3]
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors